CRIS - キュ―リス （Curis Inc.）CRISのニュース
Analysts Say Curis Inc. (NASDAQ:CRIS) Can Really Get To $10.00 In 12 Months 2023/01/27 17:10:00 Marketing Sentinel
In recent trading session, Curis Inc. (NASDAQ:CRIS) saw 0.49 million shares changing hands at last check today with its beta currently measuring 2.89. Company’s recent per share price level of $0.76 trading at $0.0 or 0.91% at last check today assigns it a market valuation of $74.86M. That most recent trading price of CRIS’s stock … Analysts Say Curis Inc. (NASDAQ:CRIS) Can Really Get To $10.00 In 12 Months Read More »
Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023 - ResearchAndMarkets.com 2023/01/27 14:51:00 Kwhen Finance
Is The Stock A Good Investment? Curis, Inc. (NASDAQ:CRIS -0.21%), EVgo, Inc. (NASDAQ:EVGO -1.76%) 2023/01/25 12:26:59 Stock Equity
Curis, Inc. (NASDAQ:CRIS) with the stream of -0.21% also noticed, India EVgo, Inc. (NASDAQ:EVGO) encountered a rapid change of -1.76% in the last hour of Tuesday’s trading session. Curis, Inc. … The post Is The Stock A Good Investment? Curis, Inc. (NASDAQ:CRIS -0.21%), EVgo, Inc. (NASDAQ:EVGO -1.76%) appeared first on Stocks Equity .
Curis Inc. (NASDAQ: CRIS) – Analysts’ Revisions Point To Positive Sentiment 2023/01/04 12:30:00 Stocks Register
Curis Inc. (NASDAQ:CRIS) traded at $0.62 at close of the session on Tuesday, 01/03/23, made an upward move of 12.02% on its previous day’s price. Looking at the stock we see that its previous close was $0.55 and the beta (5Y monthly) reads 2.72 with the day’s price range being $0.55 – $0.65. In terms … Curis Inc. (NASDAQ: CRIS) – Analysts’ Revisions Point To Positive Sentiment Read More »
Do investors need to be concerned about Curis Inc. (CRIS)? 2023/01/03 13:32:00 US Post News
In Friday’s session, Curis Inc. (NASDAQ:CRIS) marked $0.55 per share, down from $0.56 in the previous session. While Curis Inc. has underperformed by -1.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRIS fell by -88.47%, with highs and lows ranging from $5.27 to $0.47, whereas […]
Curis (CRIS) Q1 2022 Earnings Call Transcript 2022/05/06 05:01:00 The Motley Fool
CRIS earnings call for the period ending March 31, 2022.
Curis Inc.''s (CRIS) CEO Jim Dentzer on Q1 2022 Results - Earnings Call Transcript 2022/05/05 22:55:21 Seeking Alpha
Curis, Inc. (NASDAQ:NASDAQ:CRIS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 P.M.
Curis GAAP EPS of -$0.18 misses by $0.02, revenue of $2.06M misses by $0.49M 2022/05/05 20:10:40 Seeking Alpha
Curis press release (NASDAQ:CRIS): Q1 GAAP EPS of -$0.18 misses by $0.02.Revenue of $2.06M (-5.9% Y/Y) misses by $0.49M.Shares -2.2%.
Curis Reports First Quarter 2022 Financial Results and Business Update 2022/05/05 20:01:00 investors Curis
Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022 2022/04/28 20:00:00 investors Curis
Marin Software, QuinStreet lead postmarket gainers; Annexon, Dogness among losers 2022/01/06 22:29:07 Seeking Alpha
Gainers: Marin Software MRIN +43%, QuinStreet (QNST) +5%, Axsome Therapeutics (AXSM) +4%, CarParts.com PRTS +3%, Curis CRIS +3%.Losers: Annexon (ANNX) -5%, Dogness (DOGZ) -4%,
How Could You Make A Quick Recovery From Curis Inc. (NASDAQ: CRIS) Given A -463.67% Drop From Highs? 2021/12/18 20:00:00 Marketing Sentinel
During the last session, Curis Inc. (NASDAQ:CRIS)s traded shares were 3.56 million, with the beta value of the company hitting 2.84. At the end of the trading day, the stocks price was $4.79, reflecting an intraday gain of 7.16% or $0.32. The 52-week high for the CRIS share is $17.40, that puts it down -263.26 How Could You Make A Quick Recovery From Curis Inc. (NASDAQ: CRIS) Given A -463.67% Drop From Highs? Read More »
Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF 2021/12/15 13:00:00 investors Curis
Curis (NASDAQ:CRIS) Stock Rating Lowered by Zacks Investment Research 2021/12/14 01:34:42 Dakota Financial News
Curis (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. […]